A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)
BackgroundPolatuzumab vedotin, the first FDA-approved antibody-drug conjugate (ADC) targeting CD79b, is utilized in the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL), as well as relapsed or refractory (R/R) DLBCL. Despite its approval, c...
Spremljeno u:
| Glavni autori: | , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2024-06-01
|
| Serija: | Frontiers in Pharmacology |
| Teme: | |
| Online pristup: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1405023/full |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|